

INFORMATION TO USERS

This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer.

The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.

Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps.

Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order.

ProQuest Information and Learning
300 North Zeeb Road, Ann Arbor, MI 48106-1346 USA
800-521-0600

UMI[®]

PREVIEW

NOTE TO USERS

Page(s) not included in the original manuscript and are unavailable from the author or university. The manuscript was microfilmed as received.

170

This reproduction is the best copy available.

UMI'

PREVIEW

**DEVELOPMENT OF A COMPETITIVE EXCLUSION PRODUCT TO REDUCE THE
CARRIAGE OF *ESCHERICHIA COLI* O157:H7 IN CATTLE**

by

Divya Jaroni

A DISSERTATION

Presented to the Faculty of

The Graduate College at the University of Nebraska

In Partial Fulfillment of Requirements

For the Degree of Doctor of Philosophy

Major: Interdepartmental Area of Nutrition

Under the Supervision of Professor Terry Klopfenstein

Lincoln, Nebraska

August, 2001

UMI Number: 3022636

UMI[®]

UMI Microform 3022636

Copyright 2001 by Bell & Howell Information and Learning Company.
All rights reserved. This microform edition is protected against
unauthorized copying under Title 17, United States Code.

Bell & Howell Information and Learning Company
300 North Zeeb Road
P.O. Box 1346
Ann Arbor, MI 48106-1346

DISSERTATION TITLE

Development of a Competitive Exclusion Product to Reduce the

Carriage of Escherichia Coli O157:H7 in Cattle

BY

Divya Jaroni

SUPERVISORY COMMITTEE:

APPROVED

DATE

Terry Klopfenstein
Signature 8/1/01
Dr. Terry Klopfenstein
Typed Name

Mindy Brashears
Signature 8/1/01
Dr. Mindy Brashears
Typed Name

Rodney Moxley
Signature 8/1/01
Dr. Rodney Moxley
Typed Name

Robert Hutkins
Signature 8-1-01
Dr. Robert Hutkins
Typed Name

Dennis Brink
Signature 8/1/01
Dr. Dennis Brink
Typed Name

Signature _____

Typed Name



DEVELOPMENT OF A COMPETITIVE EXCLUSION PRODUCT TO REDUCE THE CARRIAGE OF *ESCHERICHIA COLI* O157:H7 IN CATTLE

Divya Jaroni, Ph. D.

University of Nebraska, 2001

Advisor: Terry Klopfenstein

Several experiments were conducted to select lactic acid bacteria (LAB) for a competitive exclusion product (CEP) that would potentially inhibit *E. coli* O157:H7 in the intestinal tract of live cattle. Fecal samples from cattle that were culture negative for *E. coli* O157:H7 were collected every three weeks over a period of 12 weeks. Lactic acid bacteria were isolated from cattle feces by repeated plating over de Man-Rogosa-Sharpe (MRS)/Lactobacillus Selection (LBS) agar. Six hundred eighty-six pure colonies were isolated and each isolate was tested for inhibition of a four-strain mixture of *E. coli* O157:H7 using agar spot test. Three hundred fifty-five isolates (52%) showed significant inhibition. Seventy-five isolates showing maximum inhibition were screened for bile tolerance by monitoring growth in MRS broth with 0, 0.05, 0.15 and 0.3% oxgall over a 24 h period. Most isolates were tolerant to bile, and were subsequently identified using the Analytical Profile Index (API) system. The following strains of LAB were most commonly identified, *Lactobacillus acidophilus*, *L. fermentum*, *L. delbreukii*, *L. salivarius*, *L. brevis*, *L. cellobiosus*, *Leuconostoc* spp., and *Pediococcus acidilactici*. Well-identified strains were further tested for antibiotic resistance and inhibition towards *E. coli* O157:H7 in manure and rumen fluid. Four of the 19 strains showed susceptibility to all the antibiotics. Seven of the 19 strains (37%) significantly reduced *E. coli* counts in manure and 13 of the 19 strains (68%) significantly reduced *E. coli* counts in rumen fluid.

($P < 0.05$). Two of the isolates, M35 and L411, that were found closely related to each other by ribotyping analysis, were finally selected for CEP and further tested for acid tolerance and resistance to vancomycin, cephalosporin, and polymixin B. For acid tolerance, growth was monitored at pH 2, 4, 5, and 7 in MRS broth. Both isolates showed acid tolerance and were susceptible to the three antibiotics tested for. The 16S rRNA sequence analysis of M35 revealed its close homology to *L. crispatus*. The developed CEP will be further used in cattle feeding trials.

PREVIEW

Acknowledgements

I would like to thank my advisor, Dr. Mindy Brashears, for her constant encouragement, patience, and guidance through the entire program. This dissertation would have been impossible without her support.

I also wish to express my sincere gratitude to Dr. Terry Klopfenstein for helping me through the final steps; Dr. Rodney Moxley for taking time to read this dissertation and helping me make it better; and committee members, Dr. Dennis Brink and Dr. Robert Hutkins, for their assistance.

Special thanks to all my friends, especially: Liz, Marsha, Alejandro, and Jen for their emotional support and meaningful help during my graduate program. It would have been very difficult without you all.

Many thanks to my colleagues, Joy Trimble, Jayne Stratton, Marcos Sanchez, Wade Flukey, Lanre Makinde, Jamie Bauman, and Sara Morrissey for their combined efforts in completing this dissertation.

TABLE OF CONTENTS

I.	Literature Review	1
	A. <i>Escherichia coli</i>.....	2
	1. Introduction.....	2
	2. <i>Escherichia coli</i> O157:H7.....	4
	(a) History and Origins.....	4
	(b) Microbiology of <i>E. coli</i> O157:H7.....	5
	(c) Virulence Factors and Pathogenesis.....	7
	(d) Epidemiology.....	9
	(e) Clinical Features.....	13
	(f) Prevention and Control.....	15
	B. Probiotic.....	18
	1. Definition of Probiotics.....	18
	2. Use of Probiotics in Farm Animals.....	19
	(a) Concept of Probiotics.....	19
	(b) Probiotic Microorganisms.....	20
	3. Lactic Acid Bacteria as Probiotic Organisms.....	21
	(a) Introduction.....	21
	(b) Probiotic Effects of Lactic Acid Bacteria in Animals.....	23
	(c) Selection Criteria for Lactic Acid Bacteria	
	to be Used as Probiotics.....	29
	(d) Mechanism of Action for Competitive Exclusion.....	35
	(e) Future Prospects.....	40
	C. References.....	45
II.	Development of a Competitive Exclusion Product to Reduce the	
	Carriage of <i>Escherichia coli</i> O157:H7 in Cattle	
	A. Introduction.....	82
	B. Materials and Methods.....	87

(i)	Isolation of strains of LAB from healthy cattle.....	87
(ii)	Screening isolated colonies for inhibition towards <i>E. coli</i> O157:H7.....	88
(iii)	Test for bile tolerance.....	89
(iv)	Storage Stability.....	89
(v)	Preliminary identification of isolates using Analytical Profile Index (API).....	90
(vi)	Test for antibiotic resistance.....	90
(vii)	Test for inhibition against <i>E. coli</i> O157:H7 in rumen fluid and manure.....	92
(viii)	Identification of strains by ribotyping and 16S sequence analysis.....	94
(ix)	Test for acid tolerance and antibiotic resistance in LAB selected for CEP.....	95
(x)	Preparation of frozen concentrated cultures (FCC) of selected lactic acid bacteria.....	96
(xi)	Antagonistic effect of developed and commercial CEP on <i>E. coli</i> O157:H7 in manure and rumen fluid.....	97
(xii)	Test for interaction among lactic acid bacteria.....	98
C.	Statistical Analysis.....	98
D.	Results.....	99
(i)	Isolation of lactic acid bacteria.....	99
(ii)	Inhibition towards <i>E. coli</i> O157:H7.....	99
(iii)	Bile tolerance.....	99
(iv)	Storage Stability.....	100
(v)	Analytical Profile Index (API).....	100
(vi)	Test for antibiotic resistance.....	101
(vii)	Antagonistic action of cattle isolates against <i>E. coli</i> O157:H7 in manure and rumen fluid.....	101
(viii)	Test for acid tolerance and antibiotic resistance in	

	LAB selected for CEP.....	103
(ix)	Antagonistic effect of developed and commercial CEP on <i>E. coli</i> O157:H7 in manure and rumen fluid.....	104
(x)	Test for interaction among LAB.....	104
(xi)	Ribotyping and 16S rRNA sequence analysis	
E.	Discussion.....	106
F.	References.....	146
III.	Appendices	
A.	Appendix 1. Results of Agar Spot Test.....	158
B.	Appendix 2. Results of Bile Tolerance Test.....	163
D.	Appendix 3. Identification table for API 50CHL.....	174

List of Tables and Figures

Table 1.	Probiotic effects of lactic acid bacteria in farm animals.....	43
Table 2.	Comparison of diets fed to cattle utilized for isolation of bacteria.....	121
Table 3.	Identification of cattle isolates by Analytical Profile Index.....	122
Table 4.	Cattle isolates chosen for further analyses based on inhibition towards <i>E. coli</i> O157:H7.....	123
Table 5.	Minimum inhibitory concentrations ($\mu\text{g/ml}$) of antibiotics for cattle isolates.....	124
Table 6.	Test of antibiotic resistance in cattle isolates towards various antibiotics.....	125
Table 7.	Growth of <i>E. coli</i> O157:H7 (\log_{10} CFU/ml) in association with cattle isolates in manure at 0, 24, & 48 hours.....	126
Table 8.	Growth of <i>E. coli</i> O157:H7 (\log_{10} CFU/ml) in association with cattle isolates in rumen fluid at 0, 24, & 48 hours.....	127
Table 9.	Growth of <i>E. coli</i> O157:H7 (\log_{10} CFU/ml) in association with competitive exclusion products in manure and rumen fluid.....	128
Table 10.	Inhibition of lactic acid bacteria (M35, L411, and LA51) towards each other using agar spot test.....	129
Table 11.	Ribotyping analysis of cattle isolates as compared to the Dupont database.....	130
Table 12.	Ribotyping analysis of cattle isolates as compared to each other.....	131
Table 13.	16S rRNA sequence analysis of M35 as compared to the GenBank Database. Table shows the top five matches to Genbank.....	132
Table 14.	Acid tolerance of M35 and L411 based on their growth (\log_{10} CFU/ml) at pH 2.0, 4.0, 5.0, and 7.0 at 0, 2, 4, and 24 h.....	133

Table 15. Selection of isolates for competitive exclusion product.....134

Figure 1. Clinical features of <i>E. coli</i> O157:H7 infection.....	44
Figure 2. Nomenclature of isolates based on diets, sample collection from cattle at 1, 2, 3, and 4 weeks, and number of isolates from each sample.....	135
Figure 3. Agar Spot Test.....	136
Figure 4. Inhibition of <i>E. coli</i> O157:H7 by strains isolated from cattle fed three different diets.....	137
Figure 5. Inhibition of <i>E. coli</i> O157:H7 by lactic acid bacteria in manure.....	138
Figure 6. Inhibition of <i>E. coli</i> O157:H7 by lactic acid bacteria in rumen fluid.....	139
Figure 7. Inhibition of <i>E. coli</i> O157:H7 by competitive exclusion product in manure.....	140
Figure 8. Inhibition of <i>E. coli</i> O157:H7 by competitive exclusion product in rumen fluid.....	141
Figure 9. Ribotyping pattern of isolates H27 and C314 in comparison to Dupont database patterns.....	142
Figure 10. Ribotyping pattern of isolate R44 in comparison to Dupont database patterns.....	143
Figure 11. Ribotyping pattern of isolates C312 and T28.....	144
Figure 12. Ribotyping pattern of isolate T21 compared to Isolates A46, A43, O37, I33, M35, L411, and M38.....	145

CHAPTER I
Literature Review

PREVIEW

A. *ESCHERICHIA COLI*

1. *Introduction*

Escherichia coli, which is considered to be part of the normal flora of the intestinal tract of humans and other warm-blooded animals (67), was first described by Dr. Theodor Escherich in 1885 (75). The infant gastrointestinal tract is colonized by beneficial strains of *E. coli* within a few hours after birth (67). This bacterial population in the intestine is known to have a protective effect against pathogenic bacteria and is also necessary for synthesizing appreciable amounts of B-vitamins (230). Generally, *E. coli* strains that colonize the human intestine are harmless when confined to the intestinal lumen (168). However, they may become pathogenic and have the potential to cause infection among immuno-compromised individuals, or when the integrity of the defense barrier system of the intestinal mucosa is compromised (174).

Over the years some *E. coli* strains have developed the ability to cause disease of the gastrointestinal, urinary, or central nervous system even in healthy individuals (174). The diarrheagenic *E. coli* that have been associated with foodborne illnesses are grouped into six categories based on their pathogenic characteristics, clinical features, differences in epidemiology and distinct O:H serogroups (150). The six main categories include, enteropathogenic *E. coli* (EPEC), enteroinvasive *E. coli* (EIEC), enterotoxigenic *E. coli* (ETEC), enteroaggregative *E. coli* (EaggEC), enterohemorrhagic *E. coli* (EHEC), and diffusely adherent *E. coli* (DAEC) (171).

Enteropathogenic *E. coli* are mainly associated with neonatal and infantile diarrhea, although they are also shown to be carried by many adults without exhibiting any symptoms (274). The EPEC strains exhibit their pathogenesis by attaching and

effacing intestinal cells which has been observed in intestinal biopsy specimens from patients and can be reproduced in cell culture (10, 119, 138, 166, 211, 246, 257). The EIEC strains were first shown to be capable of causing diarrhea in volunteer studies conducted by DuPont et al. (70) and, as the name suggests, are highly invasive. They invade the colonic epithelium, multiply within the host cells, and cause necrosis of the epithelial lining resulting in bloody diarrhea (171). They have been usually linked with foodborne and waterborne outbreaks, although person-to-person transmission has also been reported (107). The incidence is thought to be low in developed countries but occasional foodborne outbreaks, such as one restaurant-associated outbreak involving 370 people in Texas, do occur (97). Enterotoxigenic *E. coli* strains are associated with two major clinical syndromes: weanling diarrhea among children in the developing countries (171), and traveler's diarrhea in the United States (65). They colonize the small intestinal mucosa and produce one or more enterotoxins belonging either to heat labile (LT1 or LT2) or heat stable family (STI or STII) (150). Some investigators have reported that ETEC strains may exhibit limited invasiveness in cell cultures, but this has not been demonstrated *in vivo* (73, 74). Enteroaggregative *E. coli* are currently defined as *E. coli* strains that do not produce enterotoxins LT or ST and that adhere to Hep-2 cells in an aggregative pattern (170, 264). They have been associated with diarrhea in developing populations, most prominently in association with persistent diarrhea (≥ 14 days) (61, 109). The fifth group of pathogenic *E. coli*, EHEC, is named after its disease-defining symptom – hemorrhagic colitis (HC) i.e. bloody diarrhea (34). However, not all EHEC infections produce blood in the stools. *E. coli* O157:H7 is one of the most important serotypes belonging to the EHEC group that has been commonly associated with HC

(209) and also hemolytic uremic syndrome (HUS) (129) around the world. Enterohemorrhagic *E. coli* strains exhibit their pathogenesis mainly by the production of Shiga toxin (1 and 2) (175, 220, 237) and adherence to the intestinal cells (2). Little is known about the pathogenesis of DAEC. They adhere to Hep-2 cells by means of a surface fimbria (F1845) which mediates the diffusely adherent (DA) phenotype (25). The limited reports on DAEC suggest that they are commonly associated with watery diarrhea especially in children older than infants (1 year to 4-5 years), and may also be important diarrheal pathogens in the developed world (171).

2. *Escherichia coli* O157:H7

(a) History and Origins:

E. coli O157:H7 was serotyped on the basis of its expression of the “157th” somatic (O) antigen and the “7th” flagellar (H) antigen (162). It was first isolated in 1975 when a woman from California was diagnosed with severe bloody diarrhea (209). The organism was first recognized as an important human pathogen in 1982, when it was implicated in two food-associated outbreaks of HC (209), a distinctive clinical entity characterized by abdominal cramps, bloody stools, and little or no fever (162). The Centers for Disease Control and Prevention (CDC) identified 47 individuals with HC and the illness was epidemiologically linked to the ingestion of hamburgers from the same fast-food restaurant chain. *E. coli* O157:H7 was isolated from the stools of about half the patients, but from none of the healthy controls (209). In the same year an outbreak of bloody diarrhea occurred in a nursing home in Canada, and *E. coli* O157:H7 was isolated from ill patients (236). These outbreak strains produced toxins active on Vero (African

green monkey kidney) and HeLa cells (122, 176). Subsequently, these strains were shown to produce toxins that were similar to Shiga toxin of *Shigella dysenteriae* and distinct from previously described *E. coli* ST and LT toxins (175). In 1983, Karmali and colleagues (129) reported an association between infection with *E. coli* that produce Shiga toxins and post-diarrheal HUS. In recognition of its distinct clinical manifestations, *E. coli* O157:H7 became the first of several serotypes referred to as EHEC, which are now believed to account for more than 90% of all cases of HUS in industrial countries (220).

E. coli O157:H7 is closely related, genetically, to *E. coli* O55:H7, an EPEC strain that is associated with infantile diarrhea (273). Similar to the EPEC strain, *E. coli* O157:H7 can adhere to epithelial cells and produce characteristic 'attaching and effacing' lesions (171). However, acquisition of additional virulence traits and the transition from O55 to O157 antigen are believed to have occurred as a result of lateral transfer and recombination (77). According to LeClerc et al. (144) *E. coli* O157:H7 may be particularly adept at incorporating foreign DNA as a result of intrinsically high rates of defects in DNA repair mechanisms

(b) Microbiology of *E. coli* O157:H7:

Most biochemical characteristics of *E. coli* O157:H7 isolates are typically the ones exhibited by other *E. coli* strains, for example, fermentation of lactose (101). However, there are some differences that set *E. coli* O157:H7 apart. These include, sorbitol fermentation (159, 271), β -glucuronidase activity (63, 250), and production of a hemolysin belonging to the α -hemolysin family (23). Unlike 80-95% of *E. coli* of human

origin, *E. coli* O157:H7 does not ferment sorbitol within 24 hours (159) and, unlike 92-96% of *E. coli*, it does not produce β -glucuronidase which is the basis for a rapid fluorogenic assay for *E. coli* (250). It also produces a hemolysin similar to the *E. coli* α -hemolysin which is encoded by the large virulence plasmid (pO157) of *E. coli* O157 strains (219). In 1988, Beutin et al. (23) had described a new type of hemolysin called enterohemolysin, and it was shown to be closely associated with Shiga-toxin-producing *E. coli* including *E. coli* O157:H7. However, further studies by Schmidt et al. (219), led to the discovery of a new EHEC hemolysin, encoded on the virulence plasmid, that was shown to be responsible for the enterohemolytic phenotype and was related but not identical to α -hemolysin.

Another important characteristic of *E. coli* O157:H7 is its inability to grow well at 44-45.5°C, the usual temperature for detecting *E. coli* in food and water (66, 200). The organism does not exhibit any unusual resistance to heat (63). The D-values for *E. coli* O157:H7 have been estimated to be 270, 45, 24, and 9.6 seconds at 57.2, 60, 62.8, and 64.3°C respectively (63). D'Aoust and co-workers (54) determined that pasteurization of milk (72°C, 16.2 s) can kill more than 10⁴ CFU/ml of *E. coli* O157:H7. As demonstrated by Raghubeer and Matches (200), the temperature range for *E. coli* O157:H7 growth and gas production in EC (*E. coli*) medium within 48 hours is 19.3 to 41°C. However, Palumbo et al. (187) found that the upper temperature for *E. coli* O157:H7 growth was culture medium-dependent; all strains grew in BHI broth at 45°C, but six of sixteen strains did not grow in EC broth. The minimum growth temperature for *E. coli* O157:H7 under otherwise optimal conditions is approximately 8-10°C (201). Doyle and Schoeni (63) demonstrated that it can also survive well in ground beef during frozen storage with

no significant changes in numbers at -80°C and -20°C for up to nine months. The number of outbreaks associated with eating ground beef, combined with the fact that the organism does not grow well at high temperatures but survives freezing, suggests that undercooked meat is the likely reason for *E. coli* O157:H7 infections.

The pathogen's survival in acidic foods is also of particular importance because of the fact that several outbreaks have been associated with low levels of *E. coli* O157:H7 surviving in acidic foods such as apple cider, fermented sausages, and apple juice. The organism grows equally well at pH 5.5 and 7.5 but growth rates decline at lower pH values, the minimum pH for growth being 4.0-4.5 (33). The organism has been experimentally shown to survive for several weeks to months in a variety of acidic foods, including mayonnaise (280), sausages (44), apple cider (279), and cheddar cheese (207) with increased rate at refrigerated temperatures.

(c) Virulence Factors and Pathogenesis:

Several factors have been associated with the virulence of *E. coli* O157:H7. One of the most important virulence characteristics is its ability to produce one or more Shiga toxins. The first of these, Shiga toxin 1, first reported as Verotoxin by Konowalchuck et al. (137) in 1977, is immunologically indistinguishable from Shiga toxin produced by *Shigella dysenteriae* type 1 (171, 175) and is also identical in biological activities i.e. cytotoxicity to HeLa cells, mouse lethality and enterotoxicity (175). The second, Shiga toxin 2, is a more divergent molecule, with only 56% amino acid homology with Shiga toxin 1 (220, 237). Both toxins consist of a single A subunit and five B subunits (177, 277). The B subunit provides tissue specificity by binding to globotriaosylceramide

(Gb3), a glycolipid of unknown function that is abundant in the cortex of the human kidney and is present in primary human endothelial cell cultures (153, 266). After endocytosis, the A subunit enzymatically inactivates the 60S ribosomal subunit, thus blocking protein synthesis (162, 180). The identification of Gb3 as the functional receptor of B subunit explains the etiologic role of *E. coli* O157:H7 in HUS, in which endothelial cells of the renal vasculature are the principal sites of damage (185). It was demonstrated in 1983 that the genes controlling the production of the two toxins are bacteriophage encoded (178, 221, 227). It is believed that the bacteriophage was acquired by the *E. coli* O157:H7 strains directly or indirectly from *Shigella* (34).

Production of Shiga toxins in itself is not sufficient to cause disease. *E. coli* O157:H7 has other characteristics that help make it virulent and deadly. Adhesion to the epithelial cells lining the intestinal tract may be one of the important aspects of the organism's pathogenic potential (101). The type of adherence demonstrated by *E. coli* O157:H7 to animal and tissue culture cells is referred to as 'attaching and effacing' (166). This is characterized by intimate adherence to the enterocyte and dissolution of the brush border at the site of attachment, with the formation of an "attaching and effacing lesion" (2, 166). During this process the bacteria make and secrete a number of proteins that affect the underlying human gut cells (2). One of these proteins that is of particular interest is intimin that acts as bacterial anchor by attaching itself to specific receptors on the human cells (2). Within the enterocyte, filamentous actin accumulates at the site of attachment and the enterocyte membrane may cup the bacteria, forming a pedestal-like structure (139). Attachment to mucosal surfaces prevents loss of bacteria into the environment (19) and promotes the delivery of toxins to euakryotic cell surfaces in a

concentrated manner (247, 278). Other factors thought to contribute to the virulence of *E. coli* O157:H7 include a 60MDa virulence plasmid (pO157) and the locus of enterocyte effacement (LEE) (162). The involvement of the 60MDa plasmid in adherence has been suggested but the reports on its exact role are conflicting (128, 253, 256, 267). It has also been suggested that the pO157 encodes a hemolysin that, in concert with specialized transport systems, may allow *E. coli* O157:H7 to use blood released into the intestine as a source of iron (142). The LEE contains genes for adhesion molecule intimin and for other factors important to the production of attaching-effacing lesions (168).

(d) Epidemiology:

In 1993-1994, CDC estimated *E. coli* O157:H7 to cause about 10,000-20,000 illnesses and close to 250 deaths per year (29, 78). However, according to a recent estimate by CDC, *E. coli* O157:H7 causes more than 73,000 human infections annually in the United States (163), a number much higher than that estimated in the past. Human infections with *E. coli* O157:H7 have also been reported in about 30 other countries including Canada (269), United Kingdom (168), Mexico (51), China (276), Argentina (156), Belgium (195) and Scotland (211, 269). These incidents have occurred in homes, day care centers, swimming pools, schools, nursing homes, and in fast-food and other restaurant operations. Although large outbreaks involving hundreds of individuals have attracted the most attention, sporadic *E. coli* O157:H7 infections comprise the major disease burden of this pathogen and appear to be more common in Canada than in the United States (101).